Expression and function of miR-155 in breast cancer

Biotechnology and Biotechnological Equipment

Volumn 29, Issue 5, 2015, Pages 840-843

  Liu, Jing ^a   Huang, WenHui ^a   Yang, HaiXia ^b   Luo, Ying ^a  

^a KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Department of Ultrasound   (China)

Author keywords

Breast cancer; miR 155; Oncogenic miRNA; Target genes

Indexed keywords

DIAGNOSIS; RNA;

BREAST CANCER; CAENORHABDITIS ELEGANS; MICRORNAS; MIR-155; ONCOGENIC MIRNA; REGULATION NETWORKS; TARGET GENES;

DISEASES;

CAENORHABDITIS ELEGANS;

EID: 84939506308     PISSN: 13102818     EISSN: None     Source Type: Journal    
DOI: 10.1080/13102818.2015.1043946     Document Type: Review

References (46)

1. Ambros V. MicroRNA pathways in flies and worms:growth, death, fat, stress, and timing. Cell. 2003;113(6):673-676.
2. Bartel DP. MicroRNAs: target recognition and regulatoryfunctions. Cell. 2009;136(2):215-233.
3. Ambros V. The functions of animal microRNAs. Nature.2004;431(7006):350-355.
4. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modu-late hematopoietic lineage differentiation. Science.2004;303(5654):83-86.
5. Xu P, Guo M, Hay BA. MicroRNAs and the regulation ofcell death. Trends Genet. 2004;20(12):617-624.
6. Jemal A, Bray F, Center MM, et al. Global cancer statis-tics. CA Cancer J Clin. 2011;61(2):69-90.
7. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA geneexpression deregulation in human breast cancer. CancerRes. 2005;65(16):7065-7070.
8. Early Breast Cancer Trialists’ Collaborative Group(EBCTCG). Effects of chemotherapy and hormonal ther-apy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687-1717.
9. Jiang S, Zhang HW, Lu MH, et al. MicroRNA-155 functions as an OncomiR in breast cancer by targeting the sup-pressor of cytokine signaling 1 gene. Cancer Res. 2010;70(8):3119-3127.
10. Clurman BE, Hayward WS. Multiple proto-oncogene acti-vations in avian leukosis virus-induced lymphomas: evidence for stage-specific events. Mol Cell Biol. 1989;9(6):2657-2664.
11. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing,often flanked by adenosines, indicates that thousands ofhuman genes are microRNA targets. Cell. 2005;120(1):15-20.
12. Heneghan HM, Miller N, Lowery AJ, et al. MicroRNAs asnovel biomarkers for breast cancer. J Oncol.2009;2009-950201.
13. Volinia S, Galasso M, Costinean S, et al. Reprogrammingof miRNA networks in cancer and leukemia. Genome Res.2010;20(5):589-599.
14. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell prolif-eration and lymphoblastic leukemia/high-grade lymphomain E(mu)-miR155 transgenic mice. Proc Natl Acad SciUSA. 2006;103(18):7024-7029.
15. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 2013;12(11):847-865.
16. Esquela-Kerscher A, Slack FJ. Oncomirs microRNAswith a role in cancer. Nat Rev Cancer. 2006;6(4):259-269.
17. Makiyama K, Hamada J, Takada M, et al. Aberrant expression of HOX genes in human invasive breast carcinoma. Oncol Rep. 2005;13(4):673-679.
18. Yang W, Lee DY, Ben-David Y. The roles of microRNAsin tumorigenesis and angiogenesis. Int J Physiol Pathophy-siol Pharmacol. 2011;3(2):140-155.
19. Kong W, He L, Coppola M, et al. MicroRNA-155 regulatescell survival, growth, and chemosensitivity by targetingFOXO3a in breast cancer. J Biol Chem. 2010;285(23):17869-17879.
20. O’Day E, Lal A. MicroRNAs and their target gene net-works in breast cancer. Breast Cancer Res. 2010;12(2):201.
21. Hui AB, Shi W, Boutros PC, et al. Robust global micro-RNA profiling with formalin-fixed paraffin-embeddedbreast cancer tissues. Lab Invest. 2009;89(5):597-606.
22. Roth C, Rack B, Muller V, et al. Circulating microRNAs asblood-based markers for patients with primary and meta-static breast cancer. Breast Cancer Res. 2010;12(6):R90.
23. Yan LX, Huang XF, Shao Q, et al. MicroRNA miR-21overexpression in human breast cancer is associated withadvanced clinical stage, lymph node metastasis and patientpoor prognosis. RNA. 2008;14(11):2348-2360.
24. Wang F, Zheng Z, Guo J, et al. Correlation and quantitation of microRNA aberrant expression in tissues and serafrom patients with breast tumor. Gynecol Oncol. 2010;119(3):586-593.
25. Zhu J, Hu XQ, Guo GL, et al. Expression and its clinicalsignificance of miR-155 in human primary breast cancer. Zhonghua Wai Ke Za Zhi. 2010;48(3):205-208. Chinese.
26. Zheng SR, Guo GL, Zhang W, et al. Clinical significanceof miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis. Oncol Rep. 2012; 27(4):1149-1155.
27. Liu J, Mao Q, Liu Y, et al. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. ChinJ Cancer Res. 2013;25(1):46-54.
28. Chen J, Wang BC, Tang JH. Clinical significance of micro-RNA-155 expression in human breast cancer. J SurgOncol. 2012;106(3):260-266.
29. Lu Z, Ye Y, Jiao D, et al. miR-155 and miR-31 are differ-entially expressed in breast cancer patients and are correlated with the estrogen receptor and progesterone receptorstatus. Oncol Lett. 2012;4(5):1027-1032.
30. Sun Y, Wang M, Lin G, et al. Serum microRNA-155 as apotential biomarker to track disease in breast cancer. PLoSOne. 2012;7(10):e47003.
31. Hafez MM, Hassan ZK, Zekri AR, et al. MicroRNAs andmetastasis-related gene expression in Egyptian breast can-cer patients. Asian Pac J Cancer Prev. 2012;13(2):591-598.
32. Volinia S, Calin GA, Liu CG, et al. A microRNAexpression signature of human solid tumors defines cancergene targets. Proc Natl Acad Sci USA. 2006; 103(7):2257-2261.
33. Blenkiron C, Goldstein LD, Thorne NP, et al. MicroRNAexpression profiling of human breast cancer identifies newmarkers of tumor subtype. Genome Biol. 2007;8(10):R214.
34. Mattiske S, Suetani RJ, Neilsen PM, et al. The oncogenicrole of miR-155 in breast cancer. Cancer Epidemiol Bio-markers Prev. 2012; 21(8):1236-1243.
35. Cortez MA, Welsh JW, Calin GA. Circulating microRNAsas noninvasive biomarkers in breast cancer. Recent ResultsCancer Res. 2012;195:151-161.
36. O’Donovan PJ, Livingston DM. BRCA1 and BRCA2:breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis. 2010;31(6):961-967.
37. Szabo CI, King MC. Inherited breast and ovarian cancer. Hum Mol Genet. 1995; 4(S1):1811-1817.
38. Chang S, Wang RH, Akagi K, et al. Tumor suppressorBRCA1 epigenetically controls oncogenic microRNA-155. Nat Med. 2011; 17(10):1275-1282.
39. Magnani L, Ballantyne EB, Zhang X, et al. PBX1 genomicpioneer function drives ERalpha signaling underlying pro-gression in breast cancer. PLoS Genet. 2011;7(11):e1002368.
40. Yue L, Li L, Liu F, et al. The oncoprotein HBXIP activatestranscriptional coregulatory protein LMO4 via Sp1 to pro-mote proliferation of breast cancer cells. Carcinogenesis.2013;34(4):927-935.
41. Zou Y, Tsai WB, Cheng CJ, et al. Forkhead box transcrip-tion factor FOXO3a suppresses estrogen-dependent breastcancer cell proliferation and tumorigenesis. Breast CancerRes. 2008;10(1):R21.
42. Sunters A, Fernandez de Mattos S, Stahl M, et al. FoxO3atranscriptional regulation of Bim controls apoptosis inpaclitaxel-treated breast cancer cell lines. J Biol Chem.2003;278(50):49795-49805.
43. Tran H, Brunet A, Grenier JM, et al. DNA repair pathwaystimulated by the forkhead transcription factor FOXO3athrough the Gadd45 protein. Science. 2002;296(5567):530-534.
44. Huang da W, Sherman BT, Lempicki RA. Systematic andintegrative analysis of large gene lists using DAVID bioin-formatics resources. Nat Protoc. 2009;4(1):44-57.
45. Huang da W, Sherman BT, Lempicki RA. Bioinformaticsenrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res.2009;37(1):1-13.
46. Kong W, Yang H, He L, et al. MicroRNA-155 is regulatedby the transforming growth factor beta/Smad pathway andcontributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28(22):6773-6784.